The French National Agency for Medicines and Health Products Safety (ANSM) has conditionally authorized AMX0035, a new medication developed by the American laboratory Amylyx Pharmaceuticals aimed at slowing the progression of Charcot foot.

Charcot foot is a serious foot complication caused by damage to small blood vessels, leading to a loss of feeling, and a change of bone and joint shape. This can alter the shape of the entire foot, put other joints at risk, and increase the risk of developing foot ulcers. Serious cases of Charcot foot can require amputation.

Ongoing doubts about the medication’s effectiveness will mean that its authorization will be highly conditional. Access will be granted as part of the “compassionate early access authorization” procedure, which allows some patients with a severe and incurable disease to have access to a medication that does not have market authorization and is typically not covered by health insurance.

To find out more, CLICK HERE.